全文获取类型
收费全文 | 409篇 |
免费 | 30篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 18篇 |
妇产科学 | 1篇 |
基础医学 | 114篇 |
口腔科学 | 2篇 |
临床医学 | 21篇 |
内科学 | 52篇 |
皮肤病学 | 2篇 |
神经病学 | 15篇 |
特种医学 | 1篇 |
外科学 | 37篇 |
综合类 | 34篇 |
预防医学 | 3篇 |
药学 | 23篇 |
中国医学 | 4篇 |
肿瘤学 | 115篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 12篇 |
2020年 | 12篇 |
2019年 | 18篇 |
2018年 | 8篇 |
2017年 | 13篇 |
2016年 | 9篇 |
2015年 | 18篇 |
2014年 | 31篇 |
2013年 | 33篇 |
2012年 | 16篇 |
2011年 | 16篇 |
2010年 | 16篇 |
2009年 | 21篇 |
2008年 | 27篇 |
2007年 | 20篇 |
2006年 | 29篇 |
2005年 | 16篇 |
2004年 | 14篇 |
2003年 | 12篇 |
2002年 | 13篇 |
2001年 | 10篇 |
2000年 | 8篇 |
1999年 | 13篇 |
1998年 | 15篇 |
1997年 | 14篇 |
1996年 | 8篇 |
1995年 | 6篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1989年 | 2篇 |
1986年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有448条查询结果,搜索用时 546 毫秒
1.
2.
一个RET原癌基因Met918Thr突变的多发性内分泌腺瘤病Ⅱb家系报道 总被引:1,自引:0,他引:1
目的 检测一个多发性内分泌腺瘤病(MEN)Ⅱb家系的RET原癌基因突变。方法 提取患者及其父母的外周血基因组DNA,对RET原癌基因第16外显子进行聚合酶链反应(PCR),将PCR扩增产物进行直接基因测序和限制性内切酶分析。结果 检测到患者RET原癌基因第16外显子918密码子存在ATG(Met)/ACG(Thr)点突变,而在患者父母中未检测到该突变。结论 通过对MENⅡb患者及其父母的基因筛查发现,该患者点突变是杂合子错义突变。该疾病的诊断达到了基因水平。 相似文献
3.
Summary. Germline mutations of the RET proto-oncogene localized on chromosome 10q11.2 are the underlying cause of hereditary medullary
thyroid carcinoma. In MEN 2A and FMTC, mutations can be found in exons 10, 11, 13 or 14. MEN 2B is characterized by a specific
mutation in exon 16. In a significant number of sporadic MTC somatic mutations in codon 918 (exon 16) are detectable. Some
rare sporadic MTC present somatic mutations in codons 611, 634, 768 and 883. Recently, deletion-insertion of the RET proto-oncogene
in exon 11 and a deletion in exon 10 has been found. RET proto-oncogene mutations are not only responsible for the development
of the familial MTC, but may also play an important role in the pathogenesis of sporadic MTC. However, the prognostic relevance
of these somatic events is still unclear.
相似文献
4.
Sobrinho-Simões M Preto A Rocha AS Castro P Máximo V Fonseca E Soares P 《Virchows Archiv : an international journal of pathology》2005,447(5):787-793
The newly discovered molecular features of well-differentiated thyroid carcinomas derived from follicular cells are reviewed,
within the frame of the 2004 WHO classification of thyroid tumours, under the following headings: “Follicular carcinoma”,
“Papillary carcinoma”, “Follicular variant of papillary carcinoma” and “Hürthle cell tumours”. A particular emphasis is put
on the meaning of PAX8–PPARγ rearrangements, RAS and BRAF mutations, and deletions and mutations of mitochondrial genes and of nuclear genes encoding for mitochondrial enzymes, for
thyroid tumorigenesis. 相似文献
5.
The evolution of cancer is a multistep phenomenon, and multiple cellular genetic lesions are involved in the emergence of
the malignant neoplasm. Several early events have been implicated in the neoplastic transformation of thyrocytes, and recent
reports have described the involvement of specific genetic alterations in different types of thyroid neoplasms: ras point mutations are frequently observed in tumours with follicular histology, gsp – the mutated form of the alpha subunit of the Gs-protein – is encountered in up to 73% of papillary or follicular thyroid
carcinomas, and a high prevalence of p53 point mutations has been found in anaplastic thyroid carcinomas but not in differentiated follicular tumours. More recent
studies revealed that the RET proto-oncogene is involved in the oncogenesis of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) by
activation of its tyrosine kinase either by point mutation or rearrangement. In this review the most important recently published
data on alterations of the RET proto-oncogene in heritable and sporadic MTCs and in PTCs will be summarized. Emphasis will be directed to the pathophysiological
mechanisms of tumour initiation, the indications and limitations of DNA testing, and the clinical implications of identified
RET defects in thyroid lesions.
Received: 9 January 1997 / Accepted: 17 February 1997 相似文献
6.
AIMS: Three cases with features of so-called 'Warthin-like tumour' of the thyroid (WaLTT) are described, in order to evaluate its relationship with papillary carcinoma (PC). METHODS AND RESULTS: We performed an histological and immunohistochemical study with emphasis on RET/PTC expression. The most striking features are represented by marked lymphocytic infiltration in the stalks of papillae and by oxyphilic metaplasia of epithelium, resembling Warthin tumour of the salivary gland. In all cases, we found nuclear features reminiscent of PC. The neoplastic cells were strongly positive for Leu M1 and epithelial membrane antigen (EMA), less for thyroglobulin and negative for calcitonin. The lymphocytic infiltrate was composed of a mixed population of B and T-cells with sparse S100-positive Langerhans cells. An interesting finding was the strong positivity with the antibody against RET/PTC. CONCLUSION: All clinicopathological data along with the presence of the extensive lymphocytic infiltrate could imply a more favourable prognosis. The expression of RET/PTC fusion gene adds support to the hypothesis that this tumour is a variant of PC, probably related to the oncocytic variant of PC. 相似文献
7.
A. Frilling W. Höppner C. Eng L. Mulligan F. Raue C. E. Broelsch 《Journal of molecular medicine (Berlin, Germany)》1995,73(5):229-233
Medullary thyroid carcinoma occurs sporadically or as a part of the inherited cancer syndrome multiple endocrine neoplasia (MEN) type 2. The MEN 2 gene has been identified as the RET proto-oncogene on chromosome 10. In MEN 2A, RET mutations are detectable in one of five cysteine codons within exons 10 and 11 and in MEN 2B in codon 918 (exon 16). Direct DNA testing for RET proto-oncogene mutations is the method of first choice in presymptomatic screening of MEN 2 families. Gene carriers should be offered prophylactic thyroidectomy. The process of DNA analysis for RET proto-oncogene mutations is demonstrated in one family with hereditary medullary thyroid carcinoma. RET mutations were detectable in five of the nine family members at risk.Abbreviations
MEN
Multiple endocrine neoplasia
-
MTC
Medullary thyroid carcinoma
-
FMTC
Familial medullary thyroid carcinoma
-
PCR
Polymerase chain reaction
-
C-cells
Calcitonin-producing parafollicular cells 相似文献
8.
先天性巨结肠与其同源病的RET基因突变的研究 总被引:4,自引:0,他引:4
目的 了解先天性巨结肠与巨结肠同源病RET基因突变及其突变的差异。方法 30例散发性先天性巨结肠,14例巨结肠同源病,10例正常对照。取外周血,提取DNA,聚合酶链反应(PCR)扩增RET基因第13外显子;单链构象多态(SSCP)分析外显子突变,并通过测序明确突变的位点和类型。结果 30例散发性先天性巨结肠RET基因13外显子检测5例存在基因突变,共发现三种突变类型:有3例在碱基18888位点,胸苷酸残基T被鸟苷酸残基G置换,导致亮氨酸的静默突变;有1例在碱基18919位点,腺苷酸残基A被鸟苷酸残基G置换,导致赖氨酸突变为谷氨酸,为错义突变;有1例在碱基18974位点,插入一个鸟苷酸残基G,导致框架移位突变。RET基因13外显子突变率为16.7%(5/30)。巨结肠同源病和正常对照组未见RET基因13外显子突变。结论 先天性巨结肠与RET基因突变有关,而巨结肠同源病未发现RET基因突变,提示这两种疾病具有分子遗传学差异。 相似文献
9.
Moran Amit Shorook Na'ara Eran Fridman Euvgeni Vladovski Tanya Wasserman Neta Milman Ziv Gil 《International journal of cancer. Journal international du cancer》2019,144(12):3014-3022
Pancreatic ductal adenocarcinoma (PDA) remains a deadly disease, affecting about 40,000 individuals in the United States annually. We aimed to characterize the role of RET as a co-driver of pancreas tumorigenesis. To assess the role of RET as a co-driver of PDA, we generated a novel triple mutant transgenic mouse based on the cre-activated p53R172H gene and a constitutively active RET M919T mutant (PRC). Survival analysis was performed using Kaplan–Meier analysis. Study of human PDA specimens and Pdx-1-Cre/KrasG12D /p53R172H (KPC) mice revealed that RET is upregulated during pancreas tumorigenesis, from inception through precursor lesions, to invasive cancer. We demonstrated that activation of RET is capable of inducing invasive pancreatic carcinomas in the background of the P53 inactivation mutation. Compared to KPC mice, PRC animals had distinct phenotypes, including longer latency to tumor progression, longer survival, and the presence of multiple macrometastases. Enhanced activation of the MAPK pathway was observed as early as the PanIN 2 stage. Sequencing of the exonic regions of KRAS in PRC-derived PDA cells revealed no evidence of KRAS mutations. RET can be an essential co-driver of pancreatic tumorigenesis in conjugation with KRAS activity. These data suggest that RET may be a potential target in the treatment of PDA. 相似文献
10.